alexa Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC) | OMICS International| Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Cancer Sci Ther/Vol.10.6 143(2018),
  • DOI: 10.4172/1948-5956.1000532

Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC)

Vieri Scotti1, Virginia Maragna1*, Fiammetta Meacci1, Maria Ausilia Teriaca1, Juliana Topulli1, Luca Visani1, Lorenzo Livi1 and Alberto Bosi2
1Department of Oncology, Radiation Oncology Unit, Azienda Ospedaliero-universitaria Careggi, , Largo, Brambilla, Firenze, Italy
2Haematology Unit, Azienda Ospedaliero-universitaria Careggi, , Largo, Brambilla, Firenze, Italy
*Corresponding Author : Virginia Maragna, Department of Oncology, Radiation Oncology Unit, Azienda Ospedaliero-universitaria Careggi, Largo, Brambilla, Firenze, Italy, Tel: +00390557947018, Email: [email protected]

Received Date: May 16, 2018 / Accepted Date: Jun 14, 2018 / Published Date: Jun 16, 2018

Abstract

Nivolumab, a humanized IgG4 programmed death-1 (PD-1) inhibitor antibody, is approved in Italy for advanced non small cell lung cancer (NSCLC), for advanced melanoma in association with ipilimumab, in second line renal cell carcinoma (RCC), in Hodgkin lymphoma relapsed after autologous stem cell transplantation and treatment with brentuximab vedotin, in head and neck squamous cell carcinoma progressed after platinum therapy and in locally advanced urothelial carcinoma unresectable or metastatic after failure of previous platinum therapy. Its immunogenic potential is well known, with described autoimmune-like syndromes, but no clear association is evident for hemolytic anemia. We report case of a 68-year-old man who developed hemolytic anemia after 28 cycles of treatment for advanced Squamous Cell Lung Cancer (SSC).

Keywords: Nivolumab; Hemolitic anemia; Squamous cell lung cancer; Hodgkin lymphoma; Anticancer effect; Carcinoma

Citation: Scotti V, Maragna V, Meacci F, Teriaca MA, Topulli J, et al. (2018) Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC). J Cancer Sci Ther 10:143-144. Doi: 10.4172/1948-5956.1000532

Copyright: © 2018 Scotti V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
Article Usage
  • Total views: 1789
  • [From(publication date): 0-2018 - Dec 09, 2019]
  • Breakdown by view type
  • HTML page views: 1741
  • PDF downloads: 48
Top